1725 TW

PATENT ATTORNEY DOCKET NO.: 053665-5010-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Louis S. KUCERA et al.

Confirmation No.: Not Available

Application No.: 10/478,738

Group Art Unit: Not Available

Filed: December 30, 2003

Examiner: Not Available

For: COMPOSITIONS AND METHODS OF

COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS Attorney Docket No.: 053665-5010-02

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, VA 22202

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.97 and 1.98, enclosed is a supplemental Form PTO-1449 which lists 245 references. Copies of the foreign patent documents and other references have been provided for the Examiner's convenience in U.S. Application No. 09/844,201, which is the parent of this application. Pursuant to the rules pertaining to applications filed after June 30, 2003, copies of the U.S. references are not enclosed. If requested, Applicants will provide the examiner with copies of the references.

It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the Form PTO-1449.

Attorney Docket No. 053665-5010-02 U.S. Application No. 10/478,738 Page 2

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), i.e., before the mailing of a first action on the merits. Accordingly, no fee is due for the submission of this Information Disclosure Statement. If any fee is deemed to be required for this submission, please charge such fee to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: October 12, 2004

I D

Paul E. Dietze

Reg. No. 45,627

CUSTOMER NO. 09629 MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004

Telephone: (202) 739-3000 Facsimile: (202) 739-3001 F REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICATION NO 10/478,738

APPLICANT

Louis S. KUCERA et al.

FILING DATE
December 30, 2003

ATTY DOCKET NO.

053665-5010-02

GROUP Not Available

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	A01	2,086,585	07/13/1937	Taub et al.	260	127	
	A02	2,087,132	07/13/1937	Taub et al.	260	127	
	A03	2,108,765	02/15/1938	Domagk	167	30	
	A04	2,209,383	07/30/1940	Bock	8	116	
	A05	2,439,969	04/20/1948	Fourneau	260	338	
	A06	2,445,393	07/20/1948	Fourneau	260	338	
	A07	2,513,747	07/04/1950	Sallman et al.	260	338	
	A08	2,606,909	08/12/1952	Blicke	260	338	
	A09	2,689,790	09/21/1954	Mowry et al.	71	2.7	
	A10	2,950,253	08/23/1960	Kling et al.	252	152	
	A11	3,054,678	09/18/1962	Michener et al.	99	150	
	A12	3,694,473	09/26/1972	Eibl et al.	260	403	
	A13	4,093,714	06/06/1978	Tolman et al.	424	180	
	A14	4,096,278	06/20/1978	Queuille	424	329	
	A15	4,119,714	10/10/1978	Kny et al.	424	199	
	A16	4,159,988	07/03/1979	Eibl et al.	260	340.9R	
	A17	4,221,732	09/09/1980	Oette et al.	260	403	
	A18	4,235,877	11/25/1980	Fullerton	424	89	
	A19	4,291,024	09/22/1981	Turcotte	424	180	
	A20	4,329,302	05/11/1982	Hanahan et al.	260	925	
	A21	4,426,525	01/17/1984	Hozumi et al.	546	22	
	A22	4,444,766	04/24/1984	Bosies et al.	424	211	
	A23	4,471,113	09/11/1984	MacCoss	536	29	
	A24	4,540,521	09/10/1985	Garst et al.	260	459	
•	A25	4,559,157	12/17/1985	Smith et al.	424	401	
	A26	4,608,392	8/26/86	Jacquet et al.	424	401	
	A27	4,619,917	10/28/1986	Lee et al.	514	77	
	A28	4,622,392	11/11/1986	Hong et al.	536	28.5	

EXAMINER

DATE CONSIDERED

ATTY DOCKET NO. APPLICATION NO 053665-5010-02 10/478,738

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP

December 30, 2003 Not Available

EFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

TO TO LOEMARY

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	A29	4,661,509	04/28/1987	Gordon et al.	514	397	
	A30	4,724,232	02/09/1988	Rideout et al.	514	50	
	A31	4,797,479	01/10/1989	Shuto et al.	536	28.5	
	A32	4,816,450	03/28/1989	Bell et al.	514	25	
	A33	4,820,508	04/11/1989	Wortzman	424	59	
	A34	4,826,823	05/02/1989	Cook et al.	514	46	
	A35	4,835,263	05/30/1989	Nguyen et al.	536	27	
	A35	4,837,023	06/06/1989	Eibl	424	439	
	A37	4,841,039	06/20/1989	Chu et al.	536	29	
	A38	4,880,782	11/14/1989	Eckstein et al.	514	45	
	A35	4,921,951	05/01/1990	Shuto et al.	536	28.5	
	A48	4,938,949	07/03/90	Borch et al.	514	476	
	A41	4,992,478	02/12/1991	Geria	514	782	
	A42	4,997,761	03/05/1991	Jett-Tilton	435	375	
	A43	5,026,687	6/25/1991	Yarchoan et al.	514	45	
	A43	5,034,394	07/23/1991	Daluge	514	261	
	A48	5,138,045	08/11/1992	Cook et al.	536	27	
	A45	5,221,696	06/22/1993	Ke et al.	514	786	
	A47	5,496,546	03/05/1996	Wang et al.	424	78.36	
	A48	5,512,671	04/30/96	Piantadosi	536	26.1	
	A49	5,614,548	03/25/1997	Piantadosi et al.	514	439	
= 77	A50	5,633,388	05/27/1997	Diana et al.	548	305.7	
	A51	5,770,584	06/23/1998	Kucera et al.	514	77	
	A52	5,830,905	11/03/1998	Diana et al.	514	322	
	A53	5,846,964	12/08/1998	Ozeki	514	182	
	A54	5,891,874	04/06/1999	Colacino et al.	514	234.5	
	A55	5,922,757	07/13/1999	Chojkier	514	458	

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-02 10/478,738

APPLICANT

FILING DATE

Louis S. KUCERA et al. December 30, 2003

GROUP Not Available

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A56	6,243,759	4/30/1999	Kucera et al.	514	77	
	A57	6,030,960	02/29/2000	Morris-Natschke et al.	514	77	
	A58	6,670,341	12/30/03	Kucera, et al.	514	77	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
 						YES	NO
B01	0 094 586	11/23/1983	EPO (English)				
B02	0 109 255	05/23/1984	EPO (English)	T			
 B03	0 142 333	05/22/1985	EPO (English)				
B04	0 145 303	06/19/1985	EPO (English)				
B05	0 146 258	06/26/1985	EPO (English)				
B06	0 252 310	01/13/1988	EPO				
 B07	0 310 109	04/05/1989	EPO (English)				
 B08	0 335 396	04/10/1989	EPO (English)				
B09	0 350 287	01/10/1990	EPO				П
 B10	0 348 859	01/03/1990	EPO (English)				Г
 B11	0 416 401	03/13/1991	EPO				
 B12	0 434 450	06/26/1991	EPO (English)				
 B13	0 506 704	07/11/1991	EPO				П
 B14	0 632 048	01/04/1995	EPO (English)				
 B15	1,561,630	03/28/1969	France	<u> </u>			
 B16	199 14 474	10/07/1999	Germany				
 B17	37 26 945 A1	02/23/1989	Germany				Г
 B18	39 34 820 A1	04/25/1991	Germany	1			
 B19	40 10 228 A1	10/02/1991	Germany				Г
 B20	2 239 243 A	06/26/1991	Great Britain	1			\vdash

EXAMINER

DATE CONSIDERED

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-02 10/478,738

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP
December 30, 2003 Not Available

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B21	42-13841	08/05/1967	Japan		١		
 B22	61-238793	10/24/1986	Japan				
B23	1029312	01/31/1989	Japan				
 B24	49-100224	09/21/1974	Japan				
B25	08-268890	10/15/1996	Japan				
 B26	10-101591	04/21/1998	Japan				
B27	90/00555	01/25/1990	WIPO				
 B28	90/05736	05/31/1990	WIPO (English)				
B29	90/15601	12/20/1990	WIPO (English)				
 B30	91/05558	05/02/1991	WIPO				
 B31	91/09602	07/11/1991	WIPO				
 B32	91/19726	12/26/1991	WIPO				
 B33	91/18914	12/12/1991	WIPO (English)				
B34	92/03462	03/05/1992	WIPO				
 B35	92/06192	04/16/1992	WIPO (English)				
B36	93/08807	05/13/1993	WIPO (English)				
 B37	93/00910	01/21/1993	WIPO				
 B38	93/16091	08/19/1993	WIPO				
 B39	93/16092	08/19/1993	WIPO				T
 B40	93/17020	09/02/1993	WIPO (English)				1
 B41	93/21191	10/28/1993	WIPO (English)				T
 B42	WO 94/28908	12/22/1994	WIPO				\top
 B43	WO 98/22496	5/28/1998	WIPO (English)				T
 B44	WO 98/17679	4/30/1998	WIPO (English)				+
 B45	WO 99/07734	2/18/1999	WIPO (English)				+

EXAMINER DATE CONSIDERED

	ATTY DOCKET NO. 053665-5010-02	APPLICATION NO 10/478,738								
RENCES CITED BY APPLICANT	APPLICANT									
(Use several sheets if necessary)	Louis S. KUCERA et al.									
	FILING DATE	GROUP								
	December 3, 2003	Not Available								
OTHER REFERENCES (Including Author, Tit	le, Date, Pertinent Pages,	Etc.)								
10, 1990										
		d Specific Inhibitors of								
		rothioate								
C04 Amari et al., "Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phas										
C05 Anderson, L. J. et al., "Antigenic Characterization of Respiratory Syncytial Virus Str										
Attwood, M. R. et al., "The Design and Synthesis of Potent In		63-4A Proteinase," Antiviral								
	, 1996									
C08 Berdel et al., "Cyto Toxicity of Thio Ether Lyso Phospho Lipids in Leukemias and Turnors of Human Origin," Can Research, Vol. 43, 5538-5543, 1983. C09 Berenguer, M. et al., "Hepatitis C Virus in the Transplant Setting," Antiviral Therapy 3(Suppl. 3):125-136, 1998 C10 Boldanova, N. B. et al., "Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis," Yopr, Med. Khim, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986)										
						C11 Bosies, E. et al., "Preparation of Lecithin Analogs as Retrovirucides and Virucides," Chemical Abstracts, 115CA; 72142p, 1991				
						Braekman et al., Proc. Amer. Soc. for Clinical Oncology, A	Abstract # 810, 1997			
Capizzi, Investigational New Drugs 14: 249-256, 1996										
C14 Chen, "Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents," Abstract American Ass of Pharmaceutical Scientists, Vol. 9, No. 10, 1992										
	OTHER REFERENCES (Including Author, Tite Aggarwal, S. K. et al., "Synthesis and Biological Evaluati 10, 1990 Alti M. et al., "Core Specific Antisense Phosphorothioate Olig Hepatinis C Viral Translation." Archives of Virology 142:589. Alti M. et al., "Specific Inhibition of Hepatitis C Viral GeneEs Oligodeoxynucleotides," Hepatology 22:07-717, September Amari et al., "Specific Inhibition of Hepatitis C Viral GeneEs Oligodeoxynucleotides," Hepatology 22:07-717, September Amari et al., "Isolation of Experimental Anti-AIDS Glycer High-Performance Liquid Chromatography," Journal of Cl. Anderson, L. et al., "Antigenic Characterization of Resp Antibodies," Journal of Infectious Diseases, 151:626-633. Attwood, M. R. et al., "The Design and Synthesis of Potent In Chemistry and Chemotherapy 10:259-273, September 1999 Bartlett, Infectious Diseases in Clinical Practice, 5:172-178 Berdel et al., "Cyot Toxicity of Thio Ether Lyso Phospho I Research, Vol. 43, 5338-543, 1983. Beronguer, M. et al., "Hepatitis C Virus in the Transplant Sett Boldanova, A. et al., "Preparation of Lecithin Analogs as Retro 72142p, 1991 Brackman et al., "Preparation of Lecithin Analogs as Retro 72142p, 1991 Brackman et al., Proc., Amer. Soc., for Clinical Oncology, A Capitzzi, Investigational New Drugs 14: 249-256, 1996 Chen, "Design and Synthesis of Novel Nucleoside Analog	RENCES CITED BY APPLICANT (Use several sheets if necessary) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Agganval, S. K. et al., "Synthesis and Biological Evaluation of Prodrugs of Zidovudine, 10, 1990 Ali M. et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent an Hepatitis C Viral Translation," Archives of Virology 142:589-599, 1997 Alt M. et al., "Sore in Inhibition of Hepatitis C Viral GeneExpression by Antisense Phosphoroligodeoxynucleotides," Hepatology 22:707-717, September 1995 Amart et al., "Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Prethigh-Performance Liquid Chromatography, 20mal of Chromatography, 390, 153-161, Anderson, L. J. et al., "Antigenic Characterization of Respiratory Syncytial Virus Strans Antibodies," "Journal of Infectious Diseases, 131:266-633, April 1985 Attwood, M. R. et al., "The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS Chemistry and Chemotherapy 10:259-273, September 1999 Bartlett, Infectious Diseases, 11:262-634, April 1985 Berdel et al., "Cyto Toxicity of Thio Ether Lyso Phospho Lipids in Leukemias and Tume Research, Vol. 43, 5538-5543, 1983. Berenguer, M. et al., "Protective Effect of Phosphatidylcholine-Containing Liposome Hepatitis," Vopr. Med. Khuri, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract Bosies, E. et al., "Preparation of Lecithin Analogs as Retrovinicides and Virucides," Che 72142p, 1991 Brackman et al., "Froc. Amer. Soc. for Clinical Oncology, Abstract # 810, 1997 Capizzi, Investigational New Drugs 14: 249-256, 1996								

Coe et al., "Preparation of Nucleotide Mimics with Potent Inhibitory Activity Against HIV Reserve Transcriptase," J. Chem. Soe, Perkin Trans 1, 3378-3379, 1991.

C18 Crumpton, S. et al., "Novel Lipid Analogs with Cytostatic and Cytocidal Activity," Anticancer Research, Vol. 8, No. 6, pp. 1361-1366, Nov.-Dec. 1988

Treatement," Clinical Microbiology Reviews, 12:298-309, April 1999

Oniel, L. W. et al., "Alkyl-Linked Diglygerides Inhibit Protein Kinase C Activation by Diacylglycerols,"

Biochemical & Biophysical Research Communications, 151, 291-97, Feb. 29, 1988

Fungus Penicillium Griseofulvum," Bioorganic and Medicinal Chemistry Letters 9:1949-1952, 1999

Chu M. et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the

Chu M. et al., "Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from Streptomyces sp.," Tetrahedron

C20 DeClercq, Journal of Medicinal Chemistry 38: 2491-2517, 1995
C21 Del Pan et al., Proc. Amer. Soc. for Clinical Oncology, Abstract # 1384, 1997

C22 Dietzfelbinger, "Cytotoxic and Purging Effects of ET-18-OCH3 in Human Malignant Lymphoid Cell Lines in Vitro,"
Abstract 2472, Proceedings of the American Assoc. for Cancer Res., 31, 416, March 1990
(23) Domawchowske J. B. et al., "Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis and

EXAMINER

C15

C16

Letters 37:7229-7232, 1996

DATE CONSIDERED

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-02 10/478,738

APPLICANT

Louis S. KUCERA et al.

GROUP

FILING DATE Not Available December 3, 2003

OTHER REFERENCES (Including Author Title Date Pertinent Pages Etc.)

OCHA		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
	C24	Englund, J. A., "Prevention Strategies for Respiratory Syncytial Virus: Passive and Active Immunization," J. Pediatr., 135:38-44, August 1999
	C25	Eron et al., AIDS 12: F181-F189, 1998
	C26	Falsey A. R. et al., "Acute Respiratory Tract Infection in Daycare Centers for Older Persons," J. Am Geriatric Soc., 43:30-36, 1995
	C27	Falsey A. R. et al., "Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings," <u>J.Am</u> Geriatric Soc., 40:115-119, 1992
	C28	Fauci, Nature (New Biology), 384: 529-534, 1996
	C29	Fields, A. P. et al., "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor," Nature, 333, 278-80, 19 May 1988
	C30	Galderisi U. et al., "Antisense Oligonucleotides as Therapeutic Agents," Journal of Cellular Physiology, 181:251-257, 1999
	C31	Gill et al., Annals of Internal Medicine 107: 502-505, 1987
	C32	Glezen W. P. et al., "Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus," Am J Dis Child, 140:543-546, 1986
	C33	Goodman and Gilman, The Pharmacological Basis of Therapeutics, Ninth Ed., 1996
	C34	Gordeev, K. et al., "Synthesis of Thio Analogs of Platlet Activating Factor (PAF)," Abstract Bioorg, Khim.," Vol. 12, No. 7, pages 951-955, 1986
	C35	Graham, F. L. et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5-DNA," Virology, Vol. 52, pp. 456-467, 1973
	C36	Guerguerian, A. et al., "Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis: a Randomized, Placebo- Controlled Trial," Am J Resp Crit Care Med., 160:829-834, 1999
	C37	Hall C. B. et al., "Infectivity of Respiratory Syncytial Virus by Various Routes of Inoculation," Infect Immun., 33:779-783, 1981
	C38	Hall, C. B. et al., "Nosocomial Respiratory Syncytial Virus Infections," N Engl J Med., 293:1343-1346, 1975
	C39	Hall C. B. et al., "Respiratory Syncytial Virus Infections Within Families," N Engl J Med, 294:414-419, 1976
	C40	Hancock et al., "Analogs of Natural Lipids. VII. Synthesis of Cyclopentanoid Analogs of Phosphatidylcholine," Journal of Lipid Research, Vol. 23, 183-189, 1982
	C41	Harada, S. et al., "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay," Science, 229, 563-566, 9 Aug. 1985
	C42	Hayashi et al., "Antitumor Activity of a Novel Nucleotide Derivative, 5'-(1,2 Dipalmitoyl-sn-glycero-3-phospho)-5-fluorouridine (TJ14026) on Murine Tumors," Biol. Pharm. Bull., 16(8), 778-81, 1993
	C43	Henderson, F.W. et al., "Respiratory-Syncytial-Virus Infections, Reinfections, and Immunity: a Prospective, Longitudinal Study in Young Children," N Engl J Med., 300:530-534, 1979
	C44	Hendrickson, H., et al., "A Facile Asymmetric Synthesis of Glycerol Phospholipid via Tritylglycidol Prepared by the Asymmetric Epoxidation of Allyl Alcohol," Abstract Chem. Phys. Lipids, Vol. 53, No. 1, pages 115-120, 1990
	C45	Himmelmann, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro," Abstract 2448, Proceedings of the American Assoc. for Cancer Res., 31, 416, March 1990

DATE CONSIDERED

REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO. 053665-5010-02 10/478,738

APPLICANT
LOUIS S. KUCERA et al.

FILING DATE 3, 2003 Not Available

OTHER REFERENCES	(Including Author	Title Date	Pertinent Pages	Etc.)

C46	Hirsch, M. S. et al., "Antiviral Agents," Fields Virology, Third Edition, Lippincott, Raven Publishers, page 431-466, 1996
C47	Hong et al., Journal of Medicinal Chemistry 33: 1380-1386, 1990
C48	Hong et al., <u>Cancer Res</u> . 50: 4401-4406
C49	Hong, C. et al., "Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Thioether Phospholipids," Abstract J. Med. Chem., Vol. 39, No. 9, pages 1771-1777, 1996
C50	Hong, C. et al., "Nucleoside-Ether Lipid Conjugates as Biotransformed Prodrugs of Antitumor and Antiviral Nucleosides," Abstract J. Lipid Mediators Cell Signaling, Vol., 10, No. 1-2, pages 159-161, 1994
C51	Hostetler, et al., "Antiviral Activity of Phosphatidyl-Dideooxycytidine in Hepatitis B-infected Cells and Enhanced Hepatic Uptake in Mice," Antiviral Research, 59-65, 1994
C52	Hostetler et al., "Phosphatidylazidothymidine and Phosphatidyl-ddc. Assessment of Uptake in Mouse Lymphoid Tissues and Antiviral Activities in Human Immunodeficiency Virus-Infected Cells and in Rauscher Leukemia Virus- Infected Mice," Antimicrobial Agents and Chemotherapy, Dec. 2792-2797, 1994
C53	Hostetler et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," Journal of Biological Chemistry, 265: 6112-6117, 1990
C54	Hostetler et al., "Phosphatidylazidothymidine: Mechanism of Antiretroviral Action in CEM Cells," <u>Journal of Biological Chemistry</u> , 266: 11714-11717, 1990
CSS	Hruska, J. F. et al., "In Vivo Inhibition of Respiratory Syncytial Virus by Ribavirin," Antimicr Agents Chemother., 21:125-130, 1982
C56	Hsu, L. et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides," <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, 1992
C57	IMPACT RSV Study Group, "Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants," Pediatrics, 102:531-537, 1998
C58	Jahne et al., "Preparation of Carbocyclic Phosphonate Nucelosides," <u>Tetrahedron Letters</u> , Vol. 33, No. 37, 5335-5338, 1992
C59	Jayasuriya et al., Design, Synthesis, and Activity of Membrane-Disrupting Bolaphiles," J. Am. Chem. Soc., 112, 5844-5850, 1990
C60	Jia et al., "Diamide Analogues of Phosphatidylcholine as Potential Anti-AIDS Agents," J. Chem. Soc., 2521-2523, 1993.
C61	Kakiuchi N. et al., "Non-peptide Inhibitors of HCV Serine Proteinase," J. FEBS Letters, 421:217-220, 1993
C62	Kasnar, B. et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents," Nucleosides & Nucleotides, 13(1-3), pp. 459-479, 1994
C63	Kawana, F. et al., "Inhibitory Effects of Antiviral Compounds on Respiratory Syncytial Virus Replication In Vitro," Antimicrob Agents Chemother., August 31, (8):1225-30, 1987
C64	Korba, B. E. et al., "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication," Antiviral Research, 19, 55-70, 1992
C65	

EXAMINER

DATE CONSIDERED

			ATTY DOCKET NO.	APPLICATION NO	
			053665-5010-02	10/478,738	
LIST OF F	REFE	RENCES CITED BY APPLICANT	APPLICANT		
1 203	1	(Use several sheets if necessary)	Louis S. KUCERA et al.		
007 \ 2 2004	(پیو		FILING DATE	GROUP	
מכן זי זי זי	副		December 30, 2003	Not Available	
-		Krugner-Higby, L. A. et al., "Novel Membrane Interactive			
THAOEMA	C66	Interaction with CD4 ⁺ Cells," Abstract 321, 32 nd Interscient Anaheim, 164, 11-14 Oct. 1992	ce Conf. on Antimicrobial Age	nts and Chemotherappy,	
	C67	Kucera, L. S., et al., "Activity of Triciribine and Triciribine Virus Types 1 and 2k" Aids Research and Human Retroviri	uses, Vol. 9, No. 4, pp. 307-31	4, 1993	
	C68	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Ana Measured by Plaque Assay," Annuals of the New York Act			
	C69	Kucera, "Inhibition of HIV-1 Plaque Formation by a Novel			
		International Conference on AIDS, Abstract No. W.C.O. 2			
	C70	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (Abstract No. 2470, Proceedings of the American Assoc. for			
	C71	Kucera, L., et al., "Inhibition of Human Immunodeficiency			
	Synthetic Phospholipid Analogs," Antiviral Research, p. A260, 1985				
	C72	Kucera, "Investigations on Membrane Active Ether Lipid A			
		Glycoproteins and Inhibit Pathogenesis," Abstract, Innovations in Therapy of Human Viral Diseases, Symposium, Research Triangle Park, 16, 6-9 Dec. 1992			
	C73	Kucera, L.S. et al., "In Vitro Evaluation and Characterization			
		as Anti-Human Immunodeficiency Virus Type 1 Agents,"			
	C74	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet A Abstract, ICAAC Orlando, 1994	ctivating Factor with Anti-Hep	oatitis B Virus Activity,"	
	C75	Kucera, L. et al., "Novel Membrane-Interactive Ether Lipid Induce Defective Virus Formation," AIDS Research And H			
	C76	Kumar, R., et al., "Equal Inhibition of HIV Replication by			
	C/0	Stereospecificity of Lysosomal Phospholipase A1" The Jou			
	C77	Larder et al., Science 243: 1731-1734, 1989			
	C78	Lister et al., "Cyclopentanoid Analogs of Phosphatidylchol Research, Vol. 29, 1297-1308, 1988.			
	C79	Maccjak, D. J. et al., "Inhibition of Viral Replication by Nucle Hepatitis C virus RNA," <u>Hepatology</u> , 30 Abstract 995, 1999			
	C80	M. MacCoss et al., "Synthesis and Biological Activity of N			
		Round Table Nucleosides, Nucleotides and their Biological February 4-6, 1981	Applications, Antwerp, Febru	ary 4-6, p. 255-263,	
	C81	Marasco, Jr., C. J., "The Synthesis and Biological Activity			
		Kinase C Activity, Neoplastic Cell Growth, and HIV-1 Infe Chapel Hill, 1990	ectivity," Dissertation for Ph.D	., Univ. of No. Carolina,	
	C82	Marasco, C. J. et al., "Synthesis and Biological Activity of			
		Alkylglycerols as Potent Inhibitors of Protein Kincase C," March 1990			
	C83	Marasco et al., "The Synthesis and Biological Testing of A		ibitors of Protein Kinase C,"	
L		American Assoc. of Pharmaceutical Scientists Abstract, Vo	n. 9, No. 10, 1992		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
053665-5010-02	10/478,738
APPLICANT	
Louis S. KUCERA et al	
FILING DATE	GROUP
December 30, 2003	Not Available

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

- +++	C84	Marx, M. H. et al., "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-Phosphocholine," Journal of Medicinal Chemistry, Abstract, 31, 858-863, March 28, 1988
		Meert, K. L. et al., "Aerosolized Ribavirin in Mechanically Ventilated Children with Respiratory Syncytial Virus
	C85	Lower Respiratory Tract Disease: a Prospective Double-Blind Randomized Trial." Crit Care Med., Abstract 22:566-
		572, April 1994
	-	
C86		Mertes et al., "Charge-Spatial Models. cis- and trans-3- and -4- Substituted Cyclohexyl Phosphates as Analogs of 2'-
		Deoxyuridine 5'-Phosphate," J. Med. Chem., Vol. 12(5), 828-832, 1968
	C87	Meyer, K. L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel
		Anti-HIV Agents," J. Med. Chem, 34, 1377-1383, 1991
	C88	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids," AAPS Meeting, Atlanta Abstract N. MN-510, p. S-
	<u> </u>	41, 22-25 Oct. 1989
	C89	Miller, R. H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses," Proc. Natl. Acad. Sci.
		<u>USA</u> , 83, pp. 2531-2535, April 1986
	C90	Mitsuya, H. et al., "Strategies for Antiviral Therapy in AIDS," Nature, 325, 773-78, 26 February 1987
C	C91	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs," Abstract 2471,
	1001	Proceedings of the American Assoc. for Cancer Res., 31, 416 Abstract 2471, March 1990
	C92	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia."
	1052	Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics,
		Vol. 31, pp. 416, Abstract 2467, March 1990
	C93	Modest, E. J. et al., "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs," The
	C93	Pharmacological Effect of Lipids III: Role of Lipids in Cancer Research, (IN PRESS), pp. 330-337, 1989
	1	Molla, A. et al., "Human Serum Attenuates the Activity of Protease Inhibitors Toward Wild-Type and Mutuant
	C94	Human Immunodeficiency Virus," Virology, 250:255-262, 1998
		Morrey, J. D. et al., "Effects of Zidovudine on Friend Virus Complex Infection in Rfv-3" Genotype-Containing Mice
	C95	
		Used as a Model for HIV Infection," Journal of Acquired Immune Deficiency Syndromes, 3, 500-10, 1990
	C96	Morris-Natschke, S. L. et al., "Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of in
		Vitro Antineoplastic Activity," J. Med. Chem., 36:2018-2025, 1993
	C97	Morris-Natschke, S. et al. "Synthesis of Sulfur Analogues of Alkyl Lysophospholipid and Neoplastic Cell Growth
		Inhibitory Properties," J. of Med. Chem., 29, 2114-17, 1986
	C98	Mutson, M. A. et al., "Two Distinct Subtypes of Human Respiratory Syncytial Virus," The Journal of General
		Virology, 66:2111-2124, October 1985
	C99	Nara, P. L. et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human
	"	Immunodeficiency Virus Neutralizing Antibody," AIDS Research and Human Retroviruses, 3, 283-302, 1987
	C100	Noseda, A. et al., "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive
	100	A gents Against Human Tumor Cells "Cancer Research 48, 1788-1791 April 1, 1988

	C100	Agents Against Human Tumor Cells," Cancer Research, 48, 1788-1791, April 1, 1988		
EXAMINER			DATE CONSIDERED	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-02 10/478,738 APPLICANT LOUIS S. KUCERA et al. FILING DATE GROUP December 30, 2003 Not Available

OTHER REFERENCES (Including Author Title Date Pertinent Pages Etc.)

Incht		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
	C101	Noseda, A. et al., "Neoplastic Cell Inhibition with New Ether Lipids Analogs," Lipids, 22, 878-883, Nov. 1987			
	C102	Ostertag, W. et al., "Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus," Proc. Nat. Acad. Sci. USA, 71, 4980-85, Dec. 1974			
	C103	Proceedings of the American Association for Cancer Research, 81, 412, May 1990			
	C104	Diglyceride (AZT-MP-DG)," Journal of Liquid Chromatography, 16(11), 2237-2248, 1993			
	C105	Pajouhesh et al., "Synthesis of Polar Head Group Homologs of All-trans-cyclopentano-phosphatidylcholine, Phosphatidyl-N, N-Dimethylethanolamine, and Phosphatidylethanolamine," <u>Journal of Lipid Research</u> , Vol. 25, 294- 303, 1984			
	C106	Piantadosi, C. et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," J. Med. Chem., 34, 1408-14, 1991			
	C107	Pidgeon, C. et al., "Anti-HIV Drugs Conjugated to the Glycerobackbone of Phospholipids," <u>The Journal of Biological Chemistry</u> , 7773-7778, 1993			
	C108	Pidgeon C. et al., "Novel Acylated Phospholipid Drugs for AIDS," Chemical Abstract, 120:69591, 1994			
	C109	The PREVENT Study Group, "Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis," Pediatrics , 99-93-99, 1997.			
	C110	Poiesz et al., Proc. Natl Acad. Sci. U.S.A. 77: 7415-7419, 1980			
	CIII	Prince, G. A., "The Pathogenesis of Respiratory Syncytial Virus Infection in Cotton Rats," <u>Am J Pathol Abstract.</u> , 93:771-91, 1978			
	C112	Domain with Serine Proteinases,", Biochemistry 36:1598-1607, 1997			
	C113	Qiu et al., "Membrane Properties of Antiviral Phospholipids Containing Heteroatoms in the Acyl Chains," Biochemistry, 33(4), 960-72, 1994			
	C114	C. Raetz et al., "Phospholipid Derivative of Cytosine Arabinoside and its Conversion to Phosphatidylinositol by Animal Tissue," <u>Science</u> 196, 303-304, 1977			
	C115	Richman et al., New England Journal of Medicine 317: 192-197, 1987			
	C116	Rodriguez, W. J. et al., "Prospective Follow-Up and Pulmonary Functions from a Placebo-Controlled Randomized Trial of Ribavirin Therapy in Respiratory Syncytial Virus Bronchiolitis," <u>Arch Pediatr Adolesc Med.</u> 153:469-474, May 1999			
	C117 Runge et al., "Destruction of Human solid Tumors by Alkyl Lyso Phospho Lipids," <u>Journal of the National Cancer</u> Institute, Vol. 64, 1301-1306, 1980				
	C118	Abstract, 9:987-1003, December 1995			
	C119	Journal of Medicine, Vol. 313, 1289-90, Nov. 14, 1985			
	C120	Scolaro M. J. et al., "Inhibition of Virus Replication with Oligonucleotides," Chemical Abstracts, <u>117:124476</u> , 1992			
	C121	Sidoti et al., "Cytostatic Activity of New Synthetic Anti-Tumor AZA-Alkyllysophospholipids," Int. J. Cancer 51, 712-717, 1992			
	C122	Small, "Characterization of Cells Sensitive and Resistant to ET-18-OCH ₃ " <u>Abstract 2447, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416, March 1990			
EXAMINER		DATE CONSIDERED			

1-WA/2270055.1

considered. Include copy of this form with next communication to applicant.

		ATTY DOCKET NO.	APPLICATION NO		
		053665-5010-02	10/478,738		
LIST OF REFEI	RENCES CITED BY APPLICANT	APPLICANT			
PEVE	(Use several sheets if necessary)	Louis S. KUCERA et al.			
. 3/		Louis S. ROCERCT Ct al.	1		
1 2 2004 B		FILING DATE	GROUP		
<u>, v</u>		December 30, 2003	Not Available		
C124	Smith, D. W. et al., "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection," New England Journal of Medicine, 325:24-29, July 1991				
C124	Steim et al., "Lipid Conjugates of Antiretroviral Agents. I. Azidothymidine-Monophosphate-Digylceride: Anti-HIV Activity, Physical Properties, and Interaction with Plasma Proteins," <u>Biochemical and Biophysical Research</u> Communications, Vol. 171, No. 1, 451-457, 1990				
C125					
C126					
C127	Sunamoto, J. et al., "Induction of Cytotoxic T Cell," Chemical Abstracts, 117:68365, 1992				
C128	Surbone et al., Annals of Internal Medicine, 108: 534-540, 1988				
C129	Surles, J. R. et al, "Multigram Synthesis of 1-Alkylamido Phospholipids," Lipids, 28, 55-57, 1993				
C _[30] Swayze, E. E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the R82150, With Activity Against Human Immunodeficiency Virus," Biograpia, & Medical Chemistry Letters, Vol. 3, No. 4, ps 43-546, 1993					
C131	Takeshita N. et al., "An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus				
	Proteinase," Analytical Biochemistry 247:242-246, May 1, 1997 Tarnowski et al., "Effect of Lyso Lecithin and Analogs on Mouse Ascites," Cancer Research, Vol. 38, 339-344, 1978				
C132					
C133	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein- Mediated Cell Fusion," Abstracts of the 2nd National Conference on Human Retroviruses, Session 18, 1995				
C134					
C135	Novel :Phospholipid Conjugate of the Anti-HIV Agent AZT," Chemistry and Physics of Lipids, 70, 213-222, 1994				
C136	Van Wijk, G. M. et al., "Spontaneous and Protein-Mediate Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceri				
C137	Vos, G. D. et al., "Treatment of Respiratory Failure Due to Surfactant," Pediatr Pulmonol., Abstract 22:412-415, Dece		neumonia with Natural		
C138					
C139	Whimbey, E. et al., "Community Respiratory Virus Infecti Recipients," Abstract, Clin Infect Dis., 22:778-782, May 1	ons Among Hospitalized Adult	Bone Marrow Transplant		
C140	Yamaue, H. et al., "Chemosensitivity Testing with Highly Colorimetric Assay," Abstract, Eur J Cancer, 27:1258-126.	Purified Fresh Human Tumor (Cells with the MTT		
C141	Yanagawa, H. et al. "Spontaneous Formation of Superhelic 111, 4567-70, June 21, 1989	al Strands," Journal of the Ame	erican Chemical Society,		
C142	Yarchoan, R. et al., "Therapeutic Strategies in the Treatme 23, 253-263, 1988	nt of AIDS," Annual Reports in	n Medicinal Chemistry, Vol.		

EXAMINER	DATE CONSIDERED	